Latest Recruitment News

Urbanise.com Limited reported a 12.4% revenue increase in Q1 FY2026, driven by its NAB partnership, while investing heavily in its Data and Payments Integration Services (DPIS) with expected cash outflows through FY2026.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

Dalaroo Metals has broadened its gold footprint in Côte d’Ivoire with four new project acquisitions while completing initial exploration in Greenland’s critical minerals sector. A $1 million capital raise supports these strategic moves as leadership changes unfold.

Kingston Resources reported a 10% revenue increase to $15.8 million in Q1 FY26, driven by higher gold and silver output and successful flotation plant commissioning. Underground mining preparations are advancing, setting the stage for a production ramp-up.

Hiremii Limited reported a 6% revenue increase and an 18% rise in gross profit for Q1 FY26, driven by global job board integration and a successful capital raise to fuel its AI-powered recruitment platform.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Harvest Technology Group reported improved EBITDA and secured new customers across mining, defence, and border control sectors in Q1 FY2026, supported by $2.13 million raised through convertible notes and loans.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Data # 3 Limited showcased strong FY25 financial results with record $3 billion gross sales and announced key board changes at its 2025 AGM. The company projects steady growth for FY26 despite some short-term challenges.

Metals X reported a 16.6% decline in tin production at its Renison operation for Q3 2025 due to equipment and processing challenges, while cash reserves rose to $279.5 million. The company continues advancing its Rentails project and maintains strategic investments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.